Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin
Isabelle Zenklusen, Clemens Muehlan, Ivan Ulč, et al.
Clinical and Experimental Pharmacology and Physiology (2020) Vol. 47, Iss. 11, pp. 1843-1849
Closed Access | Times Cited: 13

Showing 13 citing articles:

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Daridorexant: First Approval
Anthony Markham
Drugs (2022) Vol. 82, Iss. 5, pp. 601-607
Open Access | Times Cited: 56
Orexin Receptor Antagonists and Insomnia
Xin Wu, Tao Xue, Zhouqing Chen, et al.
Current Psychiatry Reports (2022) Vol. 24, Iss. 10, pp. 509-521
Closed Access | Times Cited: 20
Risk of Enzyme- and Transporter-mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews
Jingjing Yu, Yan Wang, Isabelle Ragueneau‐Majlessi
Clinical Therapeutics (2024) Vol. 46, Iss. 6, pp. 499-508
Closed Access | Times Cited: 4
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 10, pp. 1349-1360
Closed Access | Times Cited: 17
Daridorexant for the treatment of insomnia disorder: findings and implications
Jéssica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 11, pp. 1749-1761
Closed Access | Times Cited: 12
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects
Benjamin Berger, Sander Brooks, Rob Zuiker, et al.
CNS Drugs (2020) Vol. 34, Iss. 12, pp. 1253-1266
Closed Access | Times Cited: 15
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
Wojciech Ziemichód, Karolina Grabowska, Antonina Kurowska, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6041-6041
Open Access | Times Cited: 9
Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia
Juliane Park, Kandon P. Render, Drew W. Cates
Annals of Pharmacotherapy (2023) Vol. 57, Iss. 9, pp. 1076-1087
Closed Access | Times Cited: 5
Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects
Benjamin Berger, Rüdiger Kornberger, Jasper Dingemanse
European Neuropsychopharmacology (2021) Vol. 51, pp. 90-104
Closed Access | Times Cited: 12
Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia
Jadwiga Najib, Yuliana Toderika, Lorena Dima
American Journal of Therapeutics (2023) Vol. 30, Iss. 4, pp. e360-e368
Closed Access | Times Cited: 3
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects
Marion Anliker‐Ort, Jasper Dingemanse, Luboš Janů, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 11, pp. 827-837
Closed Access | Times Cited: 1
Page 1

Scroll to top